{"ABBV": {"Ticker": "ABBV", "Company": "AbbVie", "Sector": "Health Care", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Initiated", "Organization": "SVB Leerink", "Rating_Change": "Underperform", "Target_Change": "$140"}, {"Date": "2022-05-06", "Rating": "Downgrade", "Organization": "Daiwa Securities", "Rating_Change": "Outperform to Neutral", "Target_Change": "$150"}, {"Date": "2022-04-06", "Rating": "Resumed", "Organization": "Morgan Stanley", "Rating_Change": "Overweight", "Target_Change": "$192"}, {"Date": "2022-02-28", "Rating": "Downgrade", "Organization": "UBS", "Rating_Change": "Buy to Neutral", "Target_Change": "$129 to $147"}], "Score": -0.5, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 4, "Period": "180 days", "Letter_Rating": "C", "Analists": ["Daiwa Securities", "SVB Leerink", "UBS", "Morgan Stanley"], "Price_Target": 157.25}, "AMGN": {"Ticker": "AMGN", "Company": "Amgen", "Sector": "Health Care", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Initiated", "Organization": "SVB Leerink", "Rating_Change": "Mkt Perform", "Target_Change": "$256"}], "Score": 0.0, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 1, "Period": "180 days", "Letter_Rating": "C", "Analists": ["SVB Leerink"], "Price_Target": 256.0}, "ADSK": {"Ticker": "ADSK", "Company": "Autodesk", "Sector": "Information Technology", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Downgrade", "Organization": "Deutsche Bank", "Rating_Change": "Buy to Hold", "Target_Change": "$275 to $225"}, {"Date": "2022-02-25", "Rating": "Reiterated", "Organization": "Stifel", "Rating_Change": "Buy", "Target_Change": "$310 to $285"}, {"Date": "2022-02-25", "Rating": "Reiterated", "Organization": "RBC Capital Mkts", "Rating_Change": "Outperform", "Target_Change": "$300 to $295"}, {"Date": "2022-02-25", "Rating": "Reiterated", "Organization": "Morgan Stanley", "Rating_Change": "Equal-Weight", "Target_Change": "$277 to $258"}, {"Date": "2022-02-25", "Rating": "Reiterated", "Organization": "KeyBanc Capital Markets", "Rating_Change": "Overweight", "Target_Change": "$300 to $260"}, {"Date": "2022-02-25", "Rating": "Reiterated", "Organization": "JP Morgan", "Rating_Change": "Overweight", "Target_Change": "$355 to $275"}, {"Date": "2022-02-25", "Rating": "Reiterated", "Organization": "Griffin Securities", "Rating_Change": "Buy", "Target_Change": "$340 to $300"}, {"Date": "2022-02-25", "Rating": "Reiterated", "Organization": "Goldman", "Rating_Change": "Sell", "Target_Change": "$250 to $220"}, {"Date": "2022-02-25", "Rating": "Reiterated", "Organization": "Deutsche Bank", "Rating_Change": "Buy", "Target_Change": "$330 to $275"}, {"Date": "2022-02-25", "Rating": "Reiterated", "Organization": "Citigroup", "Rating_Change": "Buy", "Target_Change": "$305 to $286"}], "Score": 1.1, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 10, "Period": "180 days", "Letter_Rating": "B", "Analists": ["Goldman", "Griffin Securities", "Deutsche Bank", "KeyBanc Capital Markets", "RBC Capital Mkts", "Stifel", "Citigroup", "JP Morgan", "Morgan Stanley"], "Price_Target": 267.9}, "ED": {"Ticker": "ED", "Company": "Consolidated Edison", "Sector": "Utilities", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Upgrade", "Organization": "Guggenheim", "Rating_Change": "Sell to Neutral", "Target_Change": "$94"}, {"Date": "2022-05-03", "Rating": "Downgrade", "Organization": "Wells Fargo", "Rating_Change": "Equal Weight to Underweight", "Target_Change": "$85 to $94"}, {"Date": "2022-04-26", "Rating": "Initiated", "Organization": "Credit Suisse", "Rating_Change": "Neutral", "Target_Change": "$100"}], "Score": -0.33, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 3, "Period": "180 days", "Letter_Rating": "C", "Analists": ["Guggenheim", "Credit Suisse", "Wells Fargo"], "Price_Target": 96.0}, "GLW": {"Ticker": "GLW", "Company": "Corning", "Sector": "Information Technology", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Downgrade", "Organization": "Citigroup", "Rating_Change": "Buy to Neutral", "Target_Change": "$46 to $37"}, {"Date": "2022-05-11", "Rating": "Downgrade", "Organization": "Barclays", "Rating_Change": "Overweight to Equal Weight", "Target_Change": "$53 to $38"}], "Score": -1.5, "Cumulative_Rating": "Underperform", "Number_of_Analysts": 2, "Period": "180 days", "Letter_Rating": "D", "Analists": ["Barclays", "Citigroup"], "Price_Target": 37.5}, "DOW": {"Ticker": "DOW", "Company": "Dow", "Sector": "Materials", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Downgrade", "Organization": "Piper Sandler", "Rating_Change": "Overweight to Neutral", "Target_Change": "$84 to $78"}, {"Date": "2022-05-20", "Rating": "Resumed", "Organization": "Credit Suisse", "Rating_Change": "Neutral", "Target_Change": "$50 to $67"}, {"Date": "2022-04-22", "Rating": "Upgrade", "Organization": "Citigroup", "Rating_Change": "Neutral to Buy", "Target_Change": "$70 to $82"}, {"Date": "2022-04-19", "Rating": "Upgrade", "Organization": "Wolfe Research", "Rating_Change": "Underperform to Peer Perform", "Target_Change": "$64"}, {"Date": "2022-04-19", "Rating": "Upgrade", "Organization": "Wolfe Research", "Rating_Change": "Peer Perform to Outperform", "Target_Change": "$64"}], "Score": 0.6, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 5, "Period": "180 days", "Letter_Rating": "B", "Analists": ["Piper Sandler", "Citigroup", "Credit Suisse", "Wolfe Research"], "Price_Target": 71.0}, "DTE": {"Ticker": "DTE", "Company": "DTE Energy", "Sector": "Utilities", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Upgrade", "Organization": "Credit Suisse", "Rating_Change": "Neutral to Outperform", "Target_Change": "$142 to $140"}, {"Date": "2022-04-26", "Rating": "Initiated", "Organization": "Credit Suisse", "Rating_Change": "Neutral", "Target_Change": "$142"}, {"Date": "2022-03-11", "Rating": "Downgrade", "Organization": "UBS", "Rating_Change": "Buy to Neutral", "Target_Change": "$136 to $133"}], "Score": 0.33, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 3, "Period": "180 days", "Letter_Rating": "C", "Analists": ["Credit Suisse", "UBS"], "Price_Target": 138.33}, "LLY": {"Ticker": "LLY", "Company": "Eli Lilly & Co", "Sector": "Health Care", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Initiated", "Organization": "SVB Leerink", "Rating_Change": "Outperform", "Target_Change": "$341"}, {"Date": "2022-04-06", "Rating": "Resumed", "Organization": "Morgan Stanley", "Rating_Change": "Overweight", "Target_Change": "$265 to $364"}, {"Date": "2022-03-10", "Rating": "Initiated", "Organization": "Daiwa Securities", "Rating_Change": "Outperform", "Target_Change": "$286"}], "Score": 2.0, "Cumulative_Rating": "Significant Outperform", "Number_of_Analysts": 3, "Period": "180 days", "Letter_Rating": "A", "Analists": ["Daiwa Securities", "SVB Leerink", "Morgan Stanley"], "Price_Target": 330.33}, "GPS": {"Ticker": "GPS", "Company": "Gap", "Sector": "Consumer Discretionary", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Downgrade", "Organization": "Citigroup", "Rating_Change": "Neutral to Sell", "Target_Change": "$13 to $8"}, {"Date": "2022-04-25", "Rating": "Upgrade", "Organization": "Guggenheim", "Rating_Change": "Neutral to Buy", "Target_Change": "$22"}, {"Date": "2022-04-18", "Rating": "Upgrade", "Organization": "Morgan Stanley", "Rating_Change": "Underweight to Equal-Weight", "Target_Change": "$14"}, {"Date": "2022-04-01", "Rating": "Downgrade", "Organization": "Barclays", "Rating_Change": "Equal Weight to Underweight", "Target_Change": "$17 to $13"}, {"Date": "2022-03-09", "Rating": "Downgrade", "Organization": "Daiwa Securities", "Rating_Change": "Neutral to Underperform", "Target_Change": "$13.75"}], "Score": -0.4, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 5, "Period": "180 days", "Letter_Rating": "C", "Analists": ["Guggenheim", "Daiwa Securities", "Barclays", "Citigroup", "Morgan Stanley"], "Price_Target": 10.4}, "GILD": {"Ticker": "GILD", "Company": "Gilead Sciences", "Sector": "Health Care", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Initiated", "Organization": "SVB Leerink", "Rating_Change": "Mkt Perform", "Target_Change": "$68"}, {"Date": "2022-02-28", "Rating": "Downgrade", "Organization": "BMO Capital Markets", "Rating_Change": "Outperform to Market Perform", "Target_Change": "$75 to $65"}], "Score": -1.0, "Cumulative_Rating": "Underperform", "Number_of_Analysts": 2, "Period": "180 days", "Letter_Rating": "D", "Analists": ["SVB Leerink", "BMO Capital Markets"], "Price_Target": 66.5}, "HPQ": {"Ticker": "HPQ", "Company": "HP", "Sector": "Information Technology", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Downgrade", "Organization": "Citigroup", "Rating_Change": "Buy to Neutral", "Target_Change": "$40 to $38"}, {"Date": "2022-04-08", "Rating": "Downgrade", "Organization": "UBS", "Rating_Change": "Buy to Neutral", "Target_Change": "$40"}, {"Date": "2022-03-31", "Rating": "Downgrade", "Organization": "Morgan Stanley", "Rating_Change": "Equal-Weight to Underweight", "Target_Change": "$34 to $31"}], "Score": -1.33, "Cumulative_Rating": "Underperform", "Number_of_Analysts": 3, "Period": "180 days", "Letter_Rating": "D", "Analists": ["Citigroup", "UBS", "Morgan Stanley"], "Price_Target": 36.33}, "JNJ": {"Ticker": "JNJ", "Company": "Johnson & Johnson", "Sector": "Health Care", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Resumed", "Organization": "SVB Leerink", "Rating_Change": "Outperform", "Target_Change": "$200"}, {"Date": "2022-04-06", "Rating": "Resumed", "Organization": "Morgan Stanley", "Rating_Change": "Equal-Weight", "Target_Change": "$173"}, {"Date": "2022-03-16", "Rating": "Downgrade", "Organization": "Bernstein", "Rating_Change": "Outperform to Mkt Perform", "Target_Change": "$180 to $183"}, {"Date": "2022-03-02", "Rating": "Resumed", "Organization": "BofA Securities", "Rating_Change": "Neutral", "Target_Change": "$185"}], "Score": 0.0, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 4, "Period": "180 days", "Letter_Rating": "C", "Analists": ["BofA Securities", "SVB Leerink", "Bernstein", "Morgan Stanley"], "Price_Target": 185.25}, "LYB": {"Ticker": "LYB", "Company": "LyondellBasell", "Sector": "Materials", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Downgrade", "Organization": "Piper Sandler", "Rating_Change": "Overweight to Neutral", "Target_Change": "$119 to $115"}, {"Date": "2022-03-22", "Rating": "Downgrade", "Organization": "BofA Securities", "Rating_Change": "Neutral to Underperform", "Target_Change": "$107 to $108"}], "Score": -2.0, "Cumulative_Rating": "Significant Underperform", "Number_of_Analysts": 2, "Period": "180 days", "Letter_Rating": "E", "Analists": ["Piper Sandler", "BofA Securities"], "Price_Target": 111.5}, "MSI": {"Ticker": "MSI", "Company": "Motorola Solutions", "Sector": "Information Technology", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Upgrade", "Organization": "Morgan Stanley", "Rating_Change": "Equal-Weight to Overweight", "Target_Change": "$240"}, {"Date": "2022-04-26", "Rating": "Initiated", "Organization": "Loop Capital", "Rating_Change": "Buy", "Target_Change": "$295"}], "Score": 2.0, "Cumulative_Rating": "Significant Outperform", "Number_of_Analysts": 2, "Period": "180 days", "Letter_Rating": "A", "Analists": ["Loop Capital", "Morgan Stanley"], "Price_Target": 267.5}, "PFE": {"Ticker": "PFE", "Company": "Pfizer", "Sector": "Health Care", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Initiated", "Organization": "SVB Leerink", "Rating_Change": "Mkt Perform", "Target_Change": "$55"}, {"Date": "2022-04-06", "Rating": "Resumed", "Organization": "Morgan Stanley", "Rating_Change": "Equal-Weight", "Target_Change": "$55"}], "Score": 0.0, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 2, "Period": "180 days", "Letter_Rating": "C", "Analists": ["SVB Leerink", "Morgan Stanley"], "Price_Target": 55.0}, "RL": {"Ticker": "RL", "Company": "Ralph Lauren Corporation", "Sector": "Consumer Discretionary", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Downgrade", "Organization": "Citigroup", "Rating_Change": "Buy to Neutral", "Target_Change": "$140 to $98"}, {"Date": "2022-04-05", "Rating": "Downgrade", "Organization": "Wells Fargo", "Rating_Change": "Overweight to Equal Weight", "Target_Change": "$135 to $110"}, {"Date": "2022-03-17", "Rating": "Upgrade", "Organization": "JP Morgan", "Rating_Change": "Neutral to Overweight", "Target_Change": "$142"}, {"Date": "2022-03-07", "Rating": "Downgrade", "Organization": "Wedbush", "Rating_Change": "Outperform to Neutral", "Target_Change": "$150 to $127"}], "Score": -0.75, "Cumulative_Rating": "Underperform", "Number_of_Analysts": 4, "Period": "180 days", "Letter_Rating": "D", "Analists": ["Wedbush", "Citigroup", "JP Morgan", "Wells Fargo"], "Price_Target": 119.25}, "O": {"Ticker": "O", "Company": "Realty Income Corporation", "Sector": "Real Estate", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Downgrade", "Organization": "Wolfe Research", "Rating_Change": "Outperform to Peer Perform", "Target_Change": "$73"}, {"Date": "2022-03-15", "Rating": "Upgrade", "Organization": "Wolfe Research", "Rating_Change": "Peer Perform to Outperform", "Target_Change": ""}], "Score": 0.0, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 2, "Period": "180 days", "Letter_Rating": "C", "Analists": ["Wolfe Research"], "Price_Target": 35.5}, "REGN": {"Ticker": "REGN", "Company": "Regeneron Pharmaceuticals", "Sector": "Health Care", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Initiated", "Organization": "SVB Leerink", "Rating_Change": "Outperform", "Target_Change": "$738"}], "Score": 2.0, "Cumulative_Rating": "Significant Outperform", "Number_of_Analysts": 1, "Period": "180 days", "Letter_Rating": "A", "Analists": ["SVB Leerink"], "Price_Target": 738.0}, "TRMB": {"Ticker": "TRMB", "Company": "Trimble", "Sector": "Information Technology", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Upgrade", "Organization": "Morgan Stanley", "Rating_Change": "Underweight to Equal-Weight", "Target_Change": "$70 to $67"}], "Score": 1.0, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 1, "Period": "180 days", "Letter_Rating": "B", "Analists": ["Morgan Stanley"], "Price_Target": 67.0}, "UAA": {"Ticker": "UAA", "Company": "Under Armour (Class A)", "Sector": "Consumer Discretionary", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Downgrade", "Organization": "Citigroup", "Rating_Change": "Buy to Neutral", "Target_Change": "$19 to $10"}, {"Date": "2022-05-19", "Rating": "Downgrade", "Organization": "Morgan Stanley", "Rating_Change": "Overweight to Equal-Weight", "Target_Change": "$14 to $11"}, {"Date": "2022-02-25", "Rating": "Upgrade", "Organization": "BTIG Research", "Rating_Change": "Sell to Neutral", "Target_Change": ""}, {"Date": "2022-02-24", "Rating": "Upgrade", "Organization": "Argus", "Rating_Change": "Hold to Buy", "Target_Change": "$19"}], "Score": 0.0, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 4, "Period": "180 days", "Letter_Rating": "C", "Analists": ["Citigroup", "BTIG Research", "Morgan Stanley", "Argus"], "Price_Target": 9.0}, "VRTX": {"Ticker": "VRTX", "Company": "Vertex Pharmaceuticals", "Sector": "Health Care", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Initiated", "Organization": "SVB Leerink", "Rating_Change": "Mkt Perform", "Target_Change": "$265"}, {"Date": "2022-05-06", "Rating": "Downgrade", "Organization": "Robert W. Baird", "Rating_Change": "Outperform to Neutral", "Target_Change": "$250"}, {"Date": "2022-05-03", "Rating": "Upgrade", "Organization": "Morgan Stanley", "Rating_Change": "Underweight to Equal-Weight", "Target_Change": "$250"}], "Score": -0.33, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 3, "Period": "180 days", "Letter_Rating": "C", "Analists": ["SVB Leerink", "Robert W. Baird", "Morgan Stanley"], "Price_Target": 255.0}, "WAB": {"Ticker": "WAB", "Company": "Wabtec", "Sector": "Industrials", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Initiated", "Organization": "Atlantic Equities", "Rating_Change": "Overweight", "Target_Change": "$101"}, {"Date": "2022-04-28", "Rating": "Upgrade", "Organization": "Wolfe Research", "Rating_Change": "Underperform to Peer Perform", "Target_Change": ""}], "Score": 1.5, "Cumulative_Rating": "Significant Outperform", "Number_of_Analysts": 2, "Period": "180 days", "Letter_Rating": "A", "Analists": ["Atlantic Equities", "Wolfe Research"], "Price_Target": 49.5}, "ZBRA": {"Ticker": "ZBRA", "Company": "Zebra Technologies", "Sector": "Information Technology", "Updated": "2022-05-23", "Rating": [{"Date": "2022-05-23", "Rating": "Upgrade", "Organization": "Morgan Stanley", "Rating_Change": "Underweight to Equal-Weight", "Target_Change": "$400 to $335"}, {"Date": "2022-04-04", "Rating": "Upgrade", "Organization": "JP Morgan", "Rating_Change": "Neutral to Overweight", "Target_Change": "$530 to $500"}], "Score": 1.5, "Cumulative_Rating": "Significant Outperform", "Number_of_Analysts": 2, "Period": "180 days", "Letter_Rating": "A", "Analists": ["JP Morgan", "Morgan Stanley"], "Price_Target": 417.5}}